• Je něco špatně v tomto záznamu ?

The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms

MH. Aswad, J. Kissova, P. Ovesna, L. Rihova, M. Penka

. 2021 ; 35 (6) : 3345-3353. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003305

BACKGROUND/AIM: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). PATIENTS AND METHODS: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. RESULTS: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. CONCLUSION: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003305
003      
CZ-PrNML
005      
20220127150347.0
007      
ta
008      
220113s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.12632 $2 doi
035    __
$a (PubMed)34697168
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Aswad, Mohamed Hussam $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic; aswad.mohamedhussam@fnbrno.cz $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    14
$a The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms / $c MH. Aswad, J. Kissova, P. Ovesna, L. Rihova, M. Penka
520    9_
$a BACKGROUND/AIM: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). PATIENTS AND METHODS: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. RESULTS: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. CONCLUSION: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
650    _2
$a trombocyty $7 D001792
650    12
$a mikropartikule $7 D055252
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a myeloproliferativní poruchy $x farmakoterapie $x genetika $7 D009196
650    12
$a nádory $7 D009369
650    12
$a trombóza $x etiologie $x genetika $7 D013927
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kissova, Jarmila $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ovesna, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Penka, Miroslav $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 35, č. 6 (2021), s. 3345-3353
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34697168 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150343 $b ABA008
999    __
$a ok $b bmc $g 1750922 $s 1154454
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 6 $d 3345-3353 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

    Možnosti archivace